OOIR: Observatory of International Research

Papers

(The H4-Index of Cancer Biology & Medicine is 26. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Eliminating cervical cancer: a global health imperative for women	229
Immunotherapy rechallenge of patients with advanced NSCLC progression after sequential treatment with third-generation EGFR-TKI and immunotherapy	138
A foundation model-enhanced CT radiomics signature for the noninvasive assessment of tertiary lymphoid structures and prediction of therapy benefit in gastric cancer	70
Artificial intelligence in breast cancer: applications and advancements	66
Early-onset gastric cancer global burden profile, trends, and contributors	63
Drugging the ‘undruggable’ KRAS: breakthroughs, challenges, and opportunities in pancreatic cancer	60
Click chemistry-driven tumor theranostics: recent advances, challenges, and future perspectives	56
Lactate drives immune resistance via a pharmaceutically reversible H3K18la-KIF20A-c-Myc-PD-L1 axis in hepatocellular carcinoma	51
Mitochondrial transplantation sensitizes chemotherapy to inhibit tumor development by enhancing anti-tumor immunity	39
The Warburg effect drives dedifferentiation through epigenetic reprogramming	38
Phase I study of chlorogenic acid injection for recurrent high-grade glioma with long-term follow-up	36
Unraveling vascular mechanisms in melanoma: roles of angiogenesis and vasculogenic mimicry in tumor progression and therapeutic resistance	34
<italic>Bifidobacterium animalis</italic> suppresses melanoma progression and activates anti-tumor immunity by inhibiting YAP1 expression in CD8<sup>+</sup> T cells	33
Lung cancer mortality trends in China from 2013 to 2021 and projections to 2030	33
Tumor-resident bacteria in gastrointestinal cancers: from regulatory mechanisms to clinical implications	32
Optimizing the cancer research landscape for the benefit of patients and society: A strategic perspective of the German Cancer Research Center (DKFZ) and its partnerships with university medical cente	32
ACSL3 regulates breast cancer progression via lipid metabolism reprogramming and the YES1/YAP axis	31
ENO1 expression and Erk phosphorylation in PDAC and their effects on tumor cell apoptosis in a hypoxic microenvironment	30
Biological mechanism and immune response of MHC-II expression in tumor cells	30
Associations between polymorphisms in leptin and leptin receptor genes and colorectal cancer survival	30
Cancer-derived exosomal circTMEM56 enhances the efficacy of HCC radiotherapy through the miR-136-5p/STING axis	30
Chinese Society of Clinical Oncology Non-small Cell Lung Cancer (CSCO NSCLC) guidelines in 2024: key update on the management of early and locally advanced NSCLC	28
Cancer stem cells: a target for overcoming therapeutic resistance and relapse	27
Stability and variability of molecular subtypes: comparative analysis of primary and metastatic triple-negative breast cancer	27
The role of radiomics in predicting the response to neoadjuvant chemotherapy for breast cancer	27

Role of the tumor microenvironment in shaping IDH-wildtype glioma plasticity, and potential therapeutic strategies	27
Immune checkpoint inhibitors: breakthroughs in cancer treatment	26